<DOC>
	<DOC>NCT02761629</DOC>
	<brief_summary>This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up in participants with Genotype 1 chronic hepatitis C (CHC), co-infected with human immunodeficiency virus type 1 (HIV-1).</brief_summary>
	<brief_title>Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Serological evidence of chronic hepatitis C infection by antihepatitis C virus (HCV) test Detectable HCVribonucleic acid (RNA) plasma level testing by Roche AMPLICOR HCV (&lt;50 International Units per milliliter [IU/mL]) (qualitative test) Chronic liver disease consistent with infection of CHC Compensated liver disease (ChildPugh Grade A) Serological evidence of infection by HIV1 test, antiHIV1 or HIV1 RNA detection Negative pregnancy urine or blood test (for women in childbearing age); additionally, all men and women of childbearing potential must agree to use two effective forms of contraception during the treatment and during the 6 months after the end of treatment Pregnant or nursing women and male partners of pregnant women Prior therapy with interferon (IFN) or ribavirin and any investigational medication less than or equal to (&lt;/=) 6 weeks before the first dose of the study drug History or other evidence of a medical condition associated with chronic liver disease further than HCV Active opportunistic infection associated with HIV and / or cancer requiring systemic therapy History of any other significant illness which in the investigator's opinion, could result in the participant's inability to meet the Protocol requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>